MCID: ACT216
MIFTS: 30

Acute Leukemia of Ambiguous Lineage

Categories: Rare diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Acute Leukemia of Ambiguous Lineage

MalaCards integrated aliases for Acute Leukemia of Ambiguous Lineage:

Name: Acute Leukemia of Ambiguous Lineage 49
Mixed Phenotype Acute Leukemia 49 69
Acute Biphenotypic Leukemia 49 69
Acute Leukemia of Indeterminate Lineage 49
Acute Leukemia of Undetermined Lineage 49
Undifferentiated Acute Leukemia 49
Acute Undifferentiated Leukemia 69
Mixed Lineage Acute Leukemia 49
Biphenotypic Acute Leukaemia 28
Biphenotypic Acute Leukemia 49
Aml with Lymphoid Markers 49
All with Myeloid Markers 49
Hybrid Acute Leukemia 49
Bal 49

Classifications:



External Ids:

Summaries for Acute Leukemia of Ambiguous Lineage

MalaCards based summary : Acute Leukemia of Ambiguous Lineage, also known as mixed phenotype acute leukemia, is related to acute biphenotypic leukemia and idiopathic acute eosinophilic pneumonia. The drugs Methotrexate and Ofloxacin have been mentioned in the context of this disorder. Affiliated tissues include myeloid, t cells and bone.

Related Diseases for Acute Leukemia of Ambiguous Lineage

Diseases related to Acute Leukemia of Ambiguous Lineage via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 82)
# Related Disease Score Top Affiliating Genes
1 acute biphenotypic leukemia 12.4
2 idiopathic acute eosinophilic pneumonia 11.0
3 acute leukemia 10.4
4 leukemia 10.4
5 mercury poisoning 10.2
6 pneumonia 10.2
7 pulmonary sarcoidosis 10.1
8 asthma 10.1
9 fibrosis of extraocular muscles, congenital, 1 10.0
10 pulmonary fibrosis 10.0
11 tumefactive multiple sclerosis 10.0
12 bronchiolitis obliterans 9.9
13 bronchiolitis 9.9
14 lung disease 9.9
15 leukemia, acute myeloid 9.9
16 lymphoid leukemia 9.9
17 myeloid leukemia 9.9
18 tetraploidy 9.9
19 ring chromosome y syndrome 9.9
20 eosinophilic pneumonia 9.9
21 pulmonary fibrosis, idiopathic 9.8
22 mycobacterium tuberculosis 1 9.8
23 aspergillosis 9.8
24 asbestosis 9.8
25 interstitial lung disease 9.8
26 extrinsic allergic alveolitis 9.8
27 heavy metal poisoning 9.8
28 streptococcal group a invasive disease 9.8
29 asbestos intoxication 9.8
30 lung cancer 9.7
31 cystic fibrosis 9.7
32 hydrops, lactic acidosis, and sideroblastic anemia 9.7
33 invasive aspergillosis 9.7
34 cryptogenic organizing pneumonia 9.7
35 lymphoma 9.7
36 respiratory failure 9.7
37 pulmonary edema 9.7
38 hemosiderosis 9.7
39 porphyria 9.7
40 nonspecific interstitial pneumonia 9.7
41 pulmonary tuberculosis 9.7
42 bronchitis 9.7
43 neuronitis 9.7
44 peritonitis 9.7
45 bronchiectasis 9.7
46 beryllium disease 9.7
47 chronic beryllium disease 9.7
48 chronic enteropathy associated with slco2a1 gene 9.7
49 gilles de la tourette syndrome 9.6
50 schizophrenia 9.6

Graphical network of the top 20 diseases related to Acute Leukemia of Ambiguous Lineage:



Diseases related to Acute Leukemia of Ambiguous Lineage

Symptoms & Phenotypes for Acute Leukemia of Ambiguous Lineage

Drugs & Therapeutics for Acute Leukemia of Ambiguous Lineage

Drugs for Acute Leukemia of Ambiguous Lineage (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 167)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 3,Phase 1,Phase 2 1959-05-2, 59-05-2 126941
2
Ofloxacin Approved Phase 3 82419-36-1 4583
3
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
4
Tacrolimus Approved, Investigational Phase 3,Phase 2 104987-11-3 445643 439492
5
Mycophenolic acid Approved Phase 3,Phase 2 24280-93-1 446541
6
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2 128794-94-5 5281078
7
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
8
Benzocaine Approved, Investigational Phase 3,Phase 2 1994-09-7, 94-09-7 2337
9
leucovorin Approved, Nutraceutical Phase 3,Phase 1,Phase 2 58-05-9 143 6006
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
11 tannic acid Approved, Nutraceutical Phase 3,Phase 2
12 Renal Agents Phase 3
13 Folic Acid Antagonists Phase 3,Phase 1,Phase 2
14 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
15 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
16 Cytochrome P-450 Enzyme Inhibitors Phase 3
17 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 1,Phase 2
18 Dermatologic Agents Phase 3,Phase 1,Phase 2
19 Vitamin B Complex Phase 3,Phase 1,Phase 2
20 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
21 Anti-Infective Agents Phase 3,Phase 1,Phase 2
22 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
23 Antimetabolites Phase 3,Phase 2,Phase 1
24 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
25 Antirheumatic Agents Phase 3,Phase 1,Phase 2
26 triamcinolone acetonide Phase 3
27 Triamcinolone diacetate Phase 3
28 Triamcinolone hexacetonide Phase 3
29 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
30 Calcineurin Inhibitors Phase 3,Phase 2
31 Antitubercular Agents Phase 3,Phase 2
32 Folate Nutraceutical Phase 3,Phase 1,Phase 2
33 Vitamin B9 Nutraceutical Phase 3,Phase 1,Phase 2
34
Cytarabine Approved, Investigational Phase 1, Phase 2 147-94-4 6253
35
Fludarabine Approved Phase 1, Phase 2 21679-14-1, 75607-67-9 30751
36
Sorafenib Approved, Investigational Phase 1, Phase 2 284461-73-0 216239 406563
37
Vidarabine Approved, Investigational Phase 1, Phase 2 24356-66-9 21704 32326
38
Busulfan Approved, Investigational Phase 2,Phase 1 55-98-1 2478
39
Hydrocortisone Approved, Vet_approved Phase 2,Phase 1 50-23-7 657311 5754
40
Clofarabine Approved, Investigational Phase 2,Phase 1 123318-82-1 119182
41
Dexamethasone Approved, Investigational, Vet_approved Phase 2,Phase 1 50-02-2 5743
42
Mitoxantrone Approved, Investigational Phase 2,Phase 1 65271-80-9 4212
43
Daunorubicin Approved Phase 2 20830-81-3 30323
44
Vincristine Approved, Investigational Phase 2,Phase 1 2068-78-2, 57-22-7 5978
45
Idarubicin Approved Phase 2,Phase 1 58957-92-9 42890
46
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
47
rituximab Approved Phase 2 174722-31-7 10201696
48
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
49
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
50
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189

Interventional clinical trials:

(show all 44)

# Name Status NCT ID Phase Drugs
1 Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation Completed NCT01371656 Phase 3 levofloxacin
2 Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention Recruiting NCT01951885 Phase 3 tacrolimus;methotrexate;Mycophenolate mofetil;Methotrexate (low dose)
3 Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT00990249 Phase 2 Busulfan;Clofarabine;Thymoglobulin
4 Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Completed NCT00372619 Phase 1, Phase 2 clofarabine;cytarabine;methotrexate
5 A Phase 2 Study of Clofarabine, Idarubicin, Cytarabine, Vincristine, and Corticosteroids - Mixed Phenotype Acute Leukemia (MPAL) Recruiting NCT02135874 Phase 2 Clofarabine;Idarubicin;Cytarabine;Vincristine;Rituximab;Dexamethasone
6 Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm Recruiting NCT03012672 Phase 2 Cladribine;Cytarabine;Mitoxantrone Hydrochloride
7 Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement Recruiting NCT02828358 Phase 2 Azacitidine;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Hydrocortisone Sodium Succinate;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Prednisolone;Thioguanine;Vincristine Sulfate
8 GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia Recruiting NCT02799147 Phase 1, Phase 2 Fludarabine monophosphate;Busulfan;Bendamustine
9 Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD Recruiting NCT02220985 Phase 2 Cyclophosphamide;Fludarabine Phosphate;Methotrexate;Mycophenolate Mofetil;Tacrolimus;Thiotepa
10 Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant Recruiting NCT03267186 Phase 2 Ibrutinib
11 Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Recruiting NCT02728050 Phase 1, Phase 2 Cladribine;Cytarabine;Mitoxantrone Hydrochloride;Sorafenib Tosylate
12 Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes Recruiting NCT01690520 Phase 2 Cyclophosphamide;Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Thiotepa
13 Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Recruiting NCT01028716 Phase 2 Cyclophosphamide;Fludarabine Phosphate;Mycophenolate Mofetil;Tacrolimus
14 Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant Recruiting NCT00796068 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Treosulfan
15 Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease Recruiting NCT00719888 Phase 2 Cyclophosphamide;Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
16 Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer Recruiting NCT00723099 Phase 2 Cyclophosphamide;Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
17 HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Recruiting NCT02793544 Phase 2 Fludarabine;Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5;Busulfan;Cyclophosphamide 50mg/kg/day IV on Days -2,-1;Cyclophosphamide 50mg/kg/day IV on Days -5,-4;Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4;Sirolimus;Mycophenolate mofetil;G-CSF;Pre-HCT Mesna on Days -6 and -5;Pre-HCT Mesna on Days -2 and -1;Pre-HCT Mesna on Days -5 and -4;Post-HCT Mesna
18 Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML) Recruiting NCT02115295 Phase 2 Cladribine;Cytarabine;Idarubicin
19 Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children Active, not recruiting NCT01858740 Phase 2 Fludarabine Phosphate;Methotrexate;Tacrolimus;Thiotepa
20 Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Active, not recruiting NCT02044796 Phase 1, Phase 2 Cladribine;Cytarabine;Mitoxantrone Hydrochloride
21 Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia Enrolling by invitation NCT03195010 Phase 2
22 Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes Not yet recruiting NCT03399773 Phase 2 Cyclophosphamide;Fludarabine;Thiotepa
23 Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies Not yet recruiting NCT02718755 Phase 2 Fludarabine;Cytarabine;Erwinase
24 Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies Terminated NCT02419755 Phase 2 Bortezomib;Vorinostat;Mitoxantrone;Cytarabine;Methotrexate;Hydrocortisone;Peg-L-Asparaginase;Erwinia L-Asparaginase;Dexamethasone;Mercaptopurine;Doxorubicin
25 Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome Completed NCT02212561 Phase 1 Selinexor;Fludarabine;Cytarabine;methotrexate/hydrocortisone/cytarabine
26 Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia Completed NCT01132573 Phase 1 entinostat;clofarabine
27 Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies Completed NCT02270788 Phase 1 Crenolanib;Sorafenib;methotrexate, hydrocortisone and cytarabine with leucovorin
28 AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia Completed NCT01431664 Phase 1 multikinase inhibitor AT9283
29 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01231919 Phase 1 Akt inhibitor MK2206
30 Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage Recruiting NCT03194932 Phase 1 Venetoclax;Cytarabine;Idarubicin;Intrathecal Triple Therapy
31 S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia Recruiting NCT01925131 Phase 1 cyclophosphamide;vincristine sulfate;prednisone
32 Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia Recruiting NCT02879695 Phase 1
33 Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders Recruiting NCT03198234 Phase 1
34 Decitabine, Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Recruiting NCT02921061 Phase 1 Cladribine;Cytarabine;Decitabine;Mitoxantrone Hydrochloride
35 Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Recruiting NCT02159495 Phase 1 cyclophosphamide;Fludarabine Phosphate
36 POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients Active, not recruiting NCT01319864 Phase 1 Plerixafor Dose Escalation
37 HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant Not yet recruiting NCT03326921 Phase 1 Fludarabine Phosphate
38 Phase I Study Of Vincristine, Doxorubicin, And Dexamethasone (VXD) Plus Ixazomib In Adults With Relapsed Or Refractory Acute Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia Terminated NCT01887587 Phase 1 MLN9708;Vincristine;Doxorubicin;Dexamethasone
39 Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia Terminated NCT00933985 Phase 1 dexrazoxane hydrochloride;doxorubicin hydrochloride;obatoclax mesylate;liposomal vincristine sulfate
40 Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR) Withdrawn NCT02578511 Phase 1 Ixazomib
41 High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia Recruiting NCT02551718 In Vitro Sensitivity-Directed Chemotherapy
42 Laboratory-Treated Donor Cord Blood Cell Infusion Following Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia Active, not recruiting NCT01701323 Cytarabine;Fludarabine Phosphate
43 Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia Active, not recruiting NCT01804101 Liposomal Cytarabine-Daunorubicin CPX-351
44 Acute Lymphoblastic Leukemia Registry at Asan Medical Center Terminated NCT01761682

Search NIH Clinical Center for Acute Leukemia of Ambiguous Lineage

Genetic Tests for Acute Leukemia of Ambiguous Lineage

Genetic tests related to Acute Leukemia of Ambiguous Lineage:

# Genetic test Affiliating Genes
1 Biphenotypic Acute Leukaemia 28

Anatomical Context for Acute Leukemia of Ambiguous Lineage

MalaCards organs/tissues related to Acute Leukemia of Ambiguous Lineage:

38
Myeloid, T Cells, Bone, B Lymphoblasts, Bone Marrow

Publications for Acute Leukemia of Ambiguous Lineage

Articles related to Acute Leukemia of Ambiguous Lineage:

(show all 11)
# Title Authors Year
1
Acute Leukemia of Ambiguous Lineage in Elderly Patients - Analysis of Survival Using Surveillance Epidemiology and End Results-Medicare Database. ( 27998706 )
2016
2
Novel r(2)(p25q31) cytogenetic abnormality in a pediatric patient with acute leukemia of ambiguous lineage. ( 25436969 )
2015
3
A rare case of acute leukemia of ambiguous lineage overexpressing C-MYC with monosomy 7 and Philadelphia chromosome. ( 26159563 )
2015
4
Acute leukemia of ambiguous lineage with trisomy 4 as the sole cytogenetic abnormality: A case report and literature review. ( 24918064 )
2014
5
MicroRNA profiling can classify acute leukemias of ambiguous lineage as either acute myeloid leukemia or acute lymphoid leukemia. ( 23444217 )
2013
6
Allo-HSCT for acute leukemia of ambiguous lineage in adults: the comparison between standard conditioning and intensified conditioning regimens. ( 23274355 )
2013
7
Two cases of near-tetraploidy in acute leukemias of ambiguous lineage. ( 24003431 )
2013
8
Case study interpretation--Portland: Case 4. Acute leukemia of ambiguous lineage, unclassifiable. ( 22431474 )
2012
9
Acute leukemia of ambiguous lineage, biphenotype, without CD34, TdT or TCR-rearrangement. ( 19687594 )
2009
10
Hybrid chemotherapy in two children with acute leukemia of ambiguous lineage. ( 16411195 )
2006
11
Erythrophagocytosis in de novo-philadelphia-positive acute leukemia of ambiguous lineage. ( 16923527 )
2006

Variations for Acute Leukemia of Ambiguous Lineage

Expression for Acute Leukemia of Ambiguous Lineage

Search GEO for disease gene expression data for Acute Leukemia of Ambiguous Lineage.

Pathways for Acute Leukemia of Ambiguous Lineage

GO Terms for Acute Leukemia of Ambiguous Lineage

Sources for Acute Leukemia of Ambiguous Lineage

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....